A look at the late-stage vaccine pipeline

In 2009, the world market for preventive vaccines totaled $22.1 billion, up from $19.0 billion in 2008, and is expected to grow at a compound annual rate of 9.7 percent to $35 billion in 2014. That's according to Kalorama Information, which has broken out a list of notable vaccines in late-stage development. Merck, GlaxoSmithKline, Sanofi Pasteur, Pfizer and Novartis combined control 83.9 percent of the world market, with GSK being the biggest vaccine seller.

As of mid-2010, Kalorama estimates there are more than 200 pediatric vaccines and many more adult preventative vaccines in development, although most are at the earliest stages of the testing process.

Source: Kalorama Information

Pediatric vaccine sales outstrip adult vaccine sales and are expected to increase at a faster rate than adult vaccines. Combination and pneumonoccal vaccines are expected to lead the growth. While adult vaccines currently make up 47.8 percent of the market, that share will likely decrease by 44.6 percent in 2014. Influenza vaccines will likely be the fastest growing segment of the adult vaccine market over the next five years.

Source: Kalorama Information

Kalorama has selected important late-stage vaccines that address vaccine preventable conditions (developmental products addressing not yet-preventable diseases will be covered in a separate report). Sanofi Pasteur, the vaccine arm of Sanofi-Aventis, leads the way with five pediatric and adult vaccines in late stage development. All vaccines listed on this chart are in Phase III trials or have already been submitted to U.S. or EU regulators for approval.

Phase III vaccines in development

Company Product Market Indication
Bavarian Nordic Imvamune Adult Smallpox
Bharat Biotech 116E Pediatric  Rotavirus
Crucell Flavimum Adult Yellow fever
GlaxoSmithKline Next-gen flu vaccine Adult Inactivated influenza for the elderly
  Hib-MenCYTT Pediatric Neisseria meningitis groups C &Y disease & Haemophilus influenzae type b
  Nimentrix Pediatric Neisseria meningitis groups A, C, W & Y disease prophylaxis
Merck V503 Adult Cervical cancer, 9 valent
Novartis Menveo Infants Pediatric Meningitis
  Menveo Adolescent Pediatric Meningitis
Sanofi Pasteur Pediacel EU Pediatric DTP, polio, Hib
  Menactra Pediatric Meningitis infant/toddler 9 - 12 months
  Adacel Pediatric DTP ages 4 - 6
  Hexaxim Pediatric DTP, Hepatitis B, polio, Hib
  IMOJEV Adult Japanese encephalitis

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.